These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 3260398)

  • 21. The quantitative measurement of autoantibodies to thyroglobulin and thyroid peroxidase by automated microparticle based immunoassays in Hashimoto's disease, Graves' disease and a follow-up study on postpartum thyroid disease.
    Gilmour J; Brownlee Y; Foster P; Geekie C; Kelly P; Robertson S; Wade E; Braun HB; Staub U; Michel G; Lazarus JH; Parkes AB
    Clin Lab; 2000; 46(1-2):57-61. PubMed ID: 10745983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of Graves' disease with the block-replace regimen of antithyroid drugs: the effect of treatment duration and immunogenetic susceptibility on relapse.
    Weetman AP; Pickerill AP; Watson P; Chatterjee VK; Edwards OM
    Q J Med; 1994 Jun; 87(6):337-41. PubMed ID: 7913766
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prognostic value of anti-TSH receptor antibodies in Basedow's disease treated with carbimazole].
    Duprey J; Izembart M; Vallée G; Goupil M
    Ann Med Interne (Paris); 1986; 137(7):555-8. PubMed ID: 3813296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methimazole treatment in Graves' disease: behaviour of CD5+B lymphocytes and regulatory T cell subsets.
    Paggi A; Amoroso A; Ferri GM; Mariotti A; Pellegrino C; Afeltra A
    Eur Rev Med Pharmacol Sci; 1998; 2(1):11-9. PubMed ID: 9825565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease.
    Schott M; Morgenthaler NG; Fritzen R; Feldkamp J; Willenberg HS; Scherbaum WA; Seissler J
    Horm Metab Res; 2004 Feb; 36(2):92-6. PubMed ID: 15002058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
    Franklyn JA; Daykin J; Holder R; Sheppard MC
    QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Late recurrence of Graves' disease.
    Lewis NP
    Br J Clin Pract; 1989 Feb; 43(2):82. PubMed ID: 2803906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decrease of concanavalin-A activated and short lived suppressor T cell function in thyrotoxicosis.
    Balázs C; Leövey A; Bordan L
    Biomedicine; 1979 Jul; 30(3):143-7. PubMed ID: 158395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of T cell subsets in Graves' disease: alterations associated with carbimazole.
    Ludgate ME; McGregor AM; Weetman AP; Ratanachaiyavong S; Lazarus JH; Hall R; Middleton GW
    Br Med J (Clin Res Ed); 1984 Feb; 288(6416):526-30. PubMed ID: 6421364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spin echo nuclear magnetic resonance studies on intact erythrocytes: changes in cellular metabolism as a consequence of carbimazole therapy.
    Reglinski J; Smith WE; Wilson R; Buchanan LM; McKillop JH; Thomson JA
    Clin Endocrinol (Oxf); 1992 Oct; 37(4):319-24. PubMed ID: 1362374
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin autoimmune syndrome in methimazole or carbimazole treated Chinese patients of Graves' disease.
    Lin HD; Chen HD; Chang PY; Lin CY; Ching KN
    Zhonghua Yi Xue Za Zhi (Taipei); 1988 Sep; 42(3):163-8. PubMed ID: 3265647
    [No Abstract]   [Full Text] [Related]  

  • 32. Insulin autoantibodies before and after carbimazole therapy in Asian Indian patients with Graves' disease.
    Goswami R; Jayasuryan N; Jaleel A; Tandon N; Kochupillai N
    Diabetes Res Clin Pract; 1998 Jun; 40(3):201-6. PubMed ID: 9716924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Increased urinary excretion of neopterin in patients with Graves-Basedow disease].
    Schreiber V; Tomsová Z; Límanová Z; Jůzová Z
    Cas Lek Cesk; 1989 Jul; 128(28):883-4. PubMed ID: 2790883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of carbimazole on thyroid autoantibody synthesis by thyroid lymphocytes.
    McLachlan SM; Pegg CA; Atherton MC; Middleton S; Young ET; Clark F; Smith BR
    J Clin Endocrinol Metab; 1985 Jun; 60(6):1237-42. PubMed ID: 3838998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thyroglobulin autoantibodies in endocrine diseases.
    Simionescu L; Dumitriu L; Balmeş E; Aman E; Zamfir-Grigorescu D; Ursu H
    Endocrinologie; 1986; 24(4):257-70. PubMed ID: 2433732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum soluble interleukin 2 receptor in hyperthyroid Graves' disease and effect of carbimazole therapy.
    Chow CC; Lai KN; Leung JC; Chan JC; Cockram CS
    Clin Endocrinol (Oxf); 1990 Sep; 33(3):317-21. PubMed ID: 2253407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The behaviour of suppressor-inducer T cells following treatment for Graves' disease.
    Wilson R; Pearson C; McKillop JH; Burnett AK; Thomson JA
    Autoimmunity; 1990; 6(1-2):93-7. PubMed ID: 2151791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patterns of change in the early (20-minute) radioiodine uptake during carbimazole treatment for Graves' disease and their relationship to outcome.
    Wilkin TJ; Isles TE; Crooks J; Gunn A; Beck JS
    J Clin Endocrinol Metab; 1981 Jun; 52(6):1067-72. PubMed ID: 6894449
    [No Abstract]   [Full Text] [Related]  

  • 39. Immunological studies of the eye changes of thyrotoxicosis.
    Wall JR; Odgers R; Hetzel BS
    Aust N Z J Med; 1973 Apr; 3(2):162-8. PubMed ID: 4515114
    [No Abstract]   [Full Text] [Related]  

  • 40. Time, carbimazole and the outcome of Graves' disease.
    Wilkin TJ; Beck JS; Crooks J; Isles TE; Gunn A
    J Endocrinol Invest; 1981; 4(4):409-11. PubMed ID: 6895905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.